Navigation Links
Medication duloxetine helps reduce pain from chemotherapy
Date:4/2/2013

Among patients with painful chemotherapy-induced peripheral neuropathy, use of the anti-depressant drug duloxetine for 5 weeks resulted in a greater reduction in pain compared with placebo, according to a study in the April 3 issue of JAMA.

"Approximately 20 percent to 40 percent of patients with cancer who receive neurotoxic chemotherapy (e.g., taxanes, platinums, vinca alkaloids, bortezomib) will develop painful chemotherapy-induced peripheral neuropathy. Painful chemotherapy-induced neuropathy can persist from months to years beyond chemotherapy completion, causing significant challenges for cancer survivors due to its negative influence on function and quality of life. Chemotherapy-induced peripheral neuropathy is difficult to manage, and most randomized controlled trials testing a variety of drugs with diverse mechanisms of action revealed no effective treatment," according to background information in the article.

There is evidence that serotonin and norepinephrine dual reuptake inhibitors are effective in treating neuropathy-related pain. Several phase 3 studies have shown that duloxetine is an effective treatment for painful diabetic neuropathy.

Ellen M. Lavoie Smith, Ph.D., of the University of Michigan School of Nursing, Ann Arbor, and colleagues conducted a randomized phase 3 trial to examine whether duloxetine would lessen chemotherapy-induced peripheral neuropathic pain. The study included 231 patients who were 25 years or older being treated at community and academic settings between April 2008 and March 2011. Study follow-up was completed July 2012. Stratified by chemotherapeutic drug and comorbid pain risk, patients were randomized to receive either duloxetine followed by placebo or placebo followed by duloxetine. Eligibility required that patients have a pain score of at least 4 on a scale of 0 to 10, representing average chemotherapy-induced pain, after paclitaxel, other taxane, or oxaliplatin treatment.

The initial treatment consisted of taking 1 capsule daily of either 30 mg of duloxetine or placebo for the first week and 2 capsules of either 30 mg of duloxetine or placebo daily for 4 additional weeks.

The researchers found that at the end of the initial treatment period, patients in the duloxetine-first group reported a larger decrease in average pain (average change score, 1.06) than those in the placebo-first group (average change score 0.34). The observed average difference in the average pain score between the duloxetine-first and placebo-first groups was 0.73. Of the patients treated with duloxetine first, 59 percent reported any decrease in pain vs. 38 percent of patients treated with placebo first. Thirty percent of duloxetine-treated patients reported no change in pain and 10 percent reported increased pain.

The authors note that the results suggested that patients who received platinums (oxaliplatin) may have experienced more benefit from duloxetine than those who received taxanes.

Pain-related quality-of-life improved to a greater degree for those treated with duloxetine during the initial treatment than for those treated with placebo.

"In conclusion, 5 weeks of duloxetine treatment was associated with a statistically and clinically significant improvement in pain compared with placebo. Exploratory analyses raise the possibility that duloxetine may work better for oxaliplatin-induced rather than taxane-induced painful chemotherapy-induced peripheral neuropathy," the researchers write.


'/>"/>

Contact: Nicole Fawcett
nfawcett@umich.edu
734-764-2220
The JAMA Network Journals
Source:Eurekalert

Related medicine news :

1. Medication with New Herbal Formula for Fallopian Tube Conditions Now Available Online
2. Parents Will Push for Medication, Even If Doc Says Not Needed
3. UCLA study finds heart failure medications highly cost-effective
4. Diet Can Lower Blood Pressure As Much As Taking A Medication, From The March 2013 Harvard Men's Health Watch
5. SiliconMesa Partners with DrFirst to Add E-prescribing and Medication Adherence Functionality to SiliconMesa EHR
6. Know Whats in Your Childs Medications, FDA Warns
7. Certain Diabetes Medications May Lower Heart Failure Risk
8. Study: Diabetic medication may protect patients from developing heart failure
9. Study: Electronic Prescribing Cuts Medication Errors
10. Cost of medication and stigma leading asthma sufferers to risk health
11. Medication Management Company Releases Compact Dispenser
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/17/2017)... York, NY (PRWEB) , ... January 17, 2017 ... ... Inc. Magazine’s fastest-growing private companies and ranked among the top US security companies ... Board of Directors. This announcement brings a year-long independent board nomination process ...
(Date:1/17/2017)... ... January 17, 2017 , ... Twelve (12) years ... Athletic Training Education program forged a relationship built upon the foundation of sports ... is consists of both student members and certified members of the Athletic Trainers’ ...
(Date:1/16/2017)... ... January 16, 2017 , ... California Southern University has named Dr. ... CalSouthern’s Board of Trustees and as a core faculty member, teaching master’s and doctoral ... professor of psychology at Pepperdine University, where he earned his Doctor of Psychology degree ...
(Date:1/16/2017)... ... 2017 , ... With the Grand Opening Event planned for February 3, 2017, ... teams and the general public. Built in five months by Centerpoint, the 60,000 square ... basketball or pickleball courts. The space is also suitable for indoor soccer and football ...
(Date:1/16/2017)... ... January 16, 2017 , ... ... announced the addition of Victor Giamos, MD to their medical staff, according to ... Partner at North Shore Eye Care, a division of SightMD. Dr. Giamos will ...
Breaking Medicine News(10 mins):
(Date:1/17/2017)... , Jan. 17, 2017 EU5 Glucose ... GlobalData,s new report, "EU5 Glucose Monitoring Market Outlook to ... Monitoring market. The report provides value, in millions of ... within market segments - Blood Glucose Meters, Blood Glucose ... company shares and distribution shares data for each of ...
(Date:1/17/2017)... , Jan. 17, 2017 The Global Nebulizers ... around 8.2% over the next decade to reach approximately ... that the market is witnessing include rapidly growing demand ... technological advancements in nebulizer products and online marketing strategies ... the market is categorized into pneumatic nebulizers, ultrasonic nebulizers ...
(Date:1/17/2017)... -- Angel MedFlight Worldwide Air Ambulance is proud to ... as the keynote speaker at the American Case Management ... D.C. April 20-23. Kelly, a former NASA ... 21 at the Gaylord National Resort.  More than 1,400 ... to attend the annual conference. Angel MedFlight is the ...
Breaking Medicine Technology: